With dosage limitations on virgin coconut oil due to its diarrheal effect, a University of the Philippines-Manila scientist leading the clinical trials on VCO as an adjunct cure for moderate to critical COVID-19 cases said that a study on the delivery using nasal spray or mouthwash is worth considering in the future.
According to researchers from University of the Philippines Manila who are conducting the clinical trial for the use of lagundi as herbal medicine in the management of mild COVID-19 cases, the plant brings “symptomatic relief” to patients without co-morbidities. Studies on the use of tawa-tawa as herbal supplement also yielded positive results.
The University of the Philippines Manila-National Institutes of Health, in partnership with the DOST-Food and Nutrition Research Institute, will be conducting research that will “determine the association of body composition with the functional capacity and quality of life of older persons in selected regions in the country.”
To help protect children with comorbidities against COVID-19, the Philippine General Hospital will be joining other government hospitals in administering vaccines that have secured Emergency Use Authorization from the Food and Drug Administration to children ages 12-17.
A 24-year-old doctor and coconut processing company executive has developed a combined virgin coconut oil (VCO) and lagundi mouth and nasal spray formula that can be a potent protection against – if not potential cure – for COVID-19.
Dr. Sterling Tiu, company doctor at his family’s coconut processing business Tropicana Food Products Inc. based in San Pablo City, Laguna, said that the combination of lagundi and VCO addresses both the cough symptoms and viral replication issues in COVID-19 cases.
The Ear Unit of the Philippine National Ear Institute resumes its operations and has taken the necessary precautions to ensure unhampered service delivery and the safety of infants who will be undergoing hearing screening.
UP health experts weigh in on how vaccine hesitancy contributes to the mutation and formation of variants of the SARS-CoV-2 virus.
The UP Surgical Innovation and Biotechnology Laboratory (UP SIBOL) is composed of engineers from the state university’s Diliman campus and clinicians from its Manila campus, who have come together to develop Filipino-made health devices.
The Department of Science and Technology-Philippine Council for Health Research and Development (DOST-PCHRD), University of The Philippines-Manila (UPM), and Fondazione Italiana Fegato (FIF) have signed a memorandum of understanding (MOU) seeking to develop and promote scientific and technological cooperation on translational hetapology through joint research and development, grant of scholarships and research fellowships, and exchange of scientists, experts and researchers for studies, and training.
The UP-PGH clinical trials on VCO had been given the green light by the Food and Drug Administration (FDA) in June last year at the height of the pandemic lockdowns in the country. Recruitment and enrollment of participants, however, started only last November.
The R&D study is one of four funded by the DOST to back up claims of the medicinal benefits of VCO especially in curing COVID-19.
